>_ QFI Terminal
TerminalStocks › VTAK

Catheter Precision, Inc. (VTAK) Stock

Healthcare · Medical - Devices · US
$0.19 -7.89%
Last updated Sep 20, 2026 15:01 UTC

VTAK Key Statistics

Market Cap$207,991.25
P/E (TTM)-0.03
P/S (TTM)0.25
P/B (TTM)31.05
Revenue (TTM)$819,000.00
EPS (TTM)$-5.76
Dividend Yield
ROE (TTM)-239.52%
Net Margin-2,086.69%
Gross Margin27.84%
52W High$2.25
52W Low$0.19
Analyst View
Price Target
Employees22
Volume18,718,378

About Catheter Precision, Inc.

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.

CEO: David A. Jenkins. Company website

VTAK — Frequently Asked Questions

What is the VTAK stock price today?

Catheter Precision, Inc. (VTAK) trades at $0.19, down 7.89% on the day, as of Sep 20, 2026 15:01 UTC.

What is Catheter Precision, Inc.'s market cap?

Catheter Precision, Inc. has a market capitalisation of $207,991.25, calculated from the live VTAK share price and shares outstanding.

What is the P/E ratio of VTAK?

VTAK has no meaningful price-to-earnings ratio: Catheter Precision, Inc. lost $5.76 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Catheter Precision, Inc. make?

Catheter Precision, Inc. generated revenue of $819,000.00 over the trailing twelve months, which puts the stock at 0.25 times sales.

What is the 52-week range for VTAK?

VTAK has traded between $0.19 and $2.25 over the past 52 weeks, and the last price is 91.4% below that high.

Is Catheter Precision, Inc. profitable?

No. Catheter Precision, Inc. is loss-making, with a net margin of -2,086.69% over the trailing twelve months.

What sector is Catheter Precision, Inc. in?

Catheter Precision, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US .

Who is the CEO of Catheter Precision, Inc.?

David A. Jenkins is the chief executive of Catheter Precision, Inc., which employs 22 people.

Where can I track VTAK in real time?

QFI Terminal shows VTAK with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See VTAK live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open VTAK in Terminal See plans

Medical - Devices stocks

ABT Abbott Laboratories MDT Medtronic plc SYK Stryker Corporation BSX Boston Scientific Corporation GEHC GE HealthCare Technologies Inc. ZBH Zimmer Biomet Holdings, Inc. EW Edwards Lifesciences Corporation SNN Smith & Nephew plc

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.